ДЖЕФФРИС Уилфред (CA);ДИКСТЕЙН Дара Л. (US);БИРОН Кан Е. (CA)
发明人:
ДЖЕФФРИС Уилфред (CA),БИРОН Кан Е. (CA),ДИКСТЕЙН Дара Л. (US)
申请号：
RU2014105495/15
公开号：
RU2014105495A
申请日:
2012.07.18
申请国别(地区):
RU
年份:
2015
代理人:
摘要：
1. A method of treating or delaying the onset of Alzheimer's disease in a patient having Alzheimer's disease or at risk of developing Alzheimer's disease, comprising administering to the subject an effective amount of an anti-angiogenic agent. A method for preserving and / or restoring the integrity of the blood-brain barrier (BBB) in a subject having Alzheimer's disease or at risk of developing Alzheimer's disease, comprising administering to the subject an effective amount of an antiangiogenic agent and / or an agent that inhibits Abeta amyloidogenesis or helps to remove the Abeta peptide from the brain .3. A method of stimulating vascular reversal in the brain of a subject having Alzheimer's disease or at risk of developing Alzheimer's disease, comprising administering to the subject an effective amount of an anti-angiogenic agent and / or an agent that helps to remove the Abeta peptide from the brain. The method according to PP. 1, 2 or 3, characterized in that the antiangiogenic agent is bexarotene, bevacizumab (Avastin®), imatinib, sorafenib, sunitinib, leflunomide (SU101), midostaurin (PKC412), watalinib (PTK787 / ZK223684, AZ4701, AG , 632, CP673, 451, RPI.4610, VEGF Trap, ZD6474, YM359445, SU5416, temsirolimus (Torisel®), batimastat, marimastat, neovastat, prinomastat, carboxyamidotriazole, TNP-470, CM101, IFN-α, IFN-α, platelet factor-4, suramin, SU5416, thrombospondin, angiostatin, endostatin, thalidomide, tetratiomolybdate, tecogalan, razoxan or reservatrol. 5. The method of claim 3, wherein the agent that facilitates removal of the Abeta peptide from the brain is an Abeta peptide or antibody that specifically binds to an Abeta peptide. Method for identifying a subject�1. Способ лечения или отдаления начала болезни Альцгеймера у пациента, имеющего болезнь Альцгеймера или подверженного риску развития болезни Альцгеймера, включающий введение субъекту эффективного количества антиангиогенного агента.2. Способ сохранения и/или восстановления целостности гемат
